Drugs / Serelaxin
Serelaxin
also known as
RLX030 · recombinant human relaxin · Human relaxin 2 (relaxin h2) · Human relaxin recombinant · recombinant human relaxin-2 · rhRlx · Serelaxina · Serelaxine
Protein / enzyme biologic targets RXFP1, RXFP2 via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Reasanz | — | 2014-08-05 | europa.eu ↗ |
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01875523 | Aug → Dec 2013 | chronic renal failure syndrome, end stage renal failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01433458 | Jul → Dec 2011 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT02625922 | Feb 2016 → Jan 2017 | heart failure | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02151383 | Sep 2014 → Apr 2017 | heart failure | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01982292 | May 2014 → Sep 2015 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01979614 | Feb 2014 → Aug 2016 | coronary artery disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02002702 | Jan → Aug 2014 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01566630 | May 2013 → Aug 2014 | preeclampsia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01640964 | Apr 2013 → Dec 2014 | portal hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01543854 | Mar 2012 → Jan 2013 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01546532 | Feb → Dec 2012 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00406575 | Nov 2006 → Jan 2007 | congestive heart failure | Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | Terminated | No outcome recorded |
| Phase 2 | NCT00259103 | Nov 2005 → Oct 2006 | — | Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02007720 | Mar 2014 → Mar 2017 | heart failure | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02064868 | Jan 2014 → Mar 2017 | heart failure | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01870778 | Oct 2013 → Jan 2017 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02669875 Comparator | Oct 2017 → Aug 2018 | cirrhosis of liver, portal hypertension | University of Edinburgh | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-03-22 | Novartis Pharmaceuticals | Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure novartis.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Serelaxin | “Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy.” PMID 31433919 ↗ Aug 201913“Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study.” PMID 25286914 ↗ Oct 2014 “AIMS: Serelaxin is a recombinant form of human relaxin-2 in development for treatment of acute heart failure.” PMID 25511105 ↗ Jun 2015 |
| Known as | Human relaxin 2 (relaxin h2) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108358 ↗ |
| Known as | Human relaxin recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108358 ↗ |
| Known as | recombinant human relaxin | “24-h intravenous infusion of serelaxin (recombinant human relaxin) or placebo for cervical ripening in 72 healthy, primiparous women.” PMID 27596360 ↗ Sep 2016 |
| Known as | recombinant human relaxin-2 | “Serelaxin (recombinant human relaxin-2) is a peptide molecule with anti-fibrotic and vasoprotective properties that binds to relaxin family peptide receptor-1 (RXFP1) and has...” PMID 28245243 ↗ Feb 2017 |
| Known as | rhRlx | “Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.” NCT00406575 ↗ |
| Known as | RLX030 | “RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.” NCT01982292 ↗4“Serelaxin (RLX030) in Patients With Compensated Cirrhosis and Portal Hypertension” NCT01640964 ↗ “Serelaxin (RLX030)” NCT01870778 ↗ |
| Known as | Serelaxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108358 ↗ |
| Known as | Serelaxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108358 ↗ |
| Action | Activate | “Relaxin receptor 2 activator” CHEMBL2108358 ↗1“Relaxin receptor 1 activator” CHEMBL2108358 ↗ |
| Modality | Protein / enzyme biologic | “24-h intravenous infusion of serelaxin (recombinant human relaxin) or placebo for cervical ripening in 72 healthy, primiparous women.” PMID 27596360 ↗ Sep 2016 |
| Route | Intravenous | “24-h intravenous infusion of serelaxin (recombinant human relaxin) or placebo for cervical ripening in 72 healthy, primiparous women.” PMID 27596360 ↗ Sep 2016 |
| Target | RXFP1 | “Relaxin receptor 1 activator” CHEMBL2108358 ↗ |
| Target | RXFP2 | “Relaxin receptor 2 activator” CHEMBL2108358 ↗ |